The global demand for Gene Therapy Market is presumed to reach the market size of nearly USD 51.8 Billion by 2032 from USD 9.67 Billion in 2023 with a CAGR of 20.5% under the study period 2024 - 2032.
Gene therapy is a medical procedure to treat or prevent some underlying genetic problem. Instead of using drugs or surgery, gene therapy is used to treat a disorder by changing/ modifying a person's genetic makeup. Many gene therapies are being studied to ensure that they are both safe and effective. Genome editing is a promising technique that doctors hope to use to treat disorders in people in the near future.
The growing field of advanced therapies and gene delivery technologies has spawned a competitive environment in which a large number of market players are attempting to commercialize their gene therapy products. Although the high prices of currently available therapies encourage more development in this field, but are also responsible for limiting the accessibility and may lead to market withdrawals due to the lack of economic viability. Biopharma companies have taken a number of steps to gain a competitive advantage in the market. Companies are pursuing various market entry strategies, including expanding biopharmaceutical facilities, collaborating with other key stakeholders, and developing products with Contract Manufacturing Organizations (CMOs).
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gene therapy. The growth and trends of gene therapy industry provide a holistic approach to this study.
This section of the gene therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Indication
By Vector Type
By Route of Administration
This section covers the regional outlook, which accentuates current and future demand for the Gene Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gene therapy market include REGENXBIO Inc., Oxford BioMedica plc, Dimension Therapeutics Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetic Technologies Corp, F. Hoffmann-La Roche Ltd., Bluebird Bio Inc., Novartis AG, Taxus Cardium Pharmaceuticals Group Inc. (Gene Biotherapeutics), UniQure N.V., Shire Plc, Cellectis S.A., Sangamo Therapeutics, Inc., Orchard Therapeutics, Gilead Lifesciences Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . GENE THERAPY – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Indication
3.7.2 Market Attractiveness Analysis By Vector Type
3.7.3 Market Attractiveness Analysis By Route of Administration
3.7.4 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL GENE THERAPY MARKET ANALYSIS BY INDICATION
5.1 Overview by Indication
5.2 Historical and Forecast Data
5.3 Analysis by Indication
5.4 Acute Lymphoblastic Leukemia (ALL) Historic and Forecast Sales by Regions
5.5 Inherited Retinal Disease Historic and Forecast Sales by Regions
5.6 Large B-cell Lymphoma Historic and Forecast Sales by Regions
5.7 ADA-SCID Historic and Forecast Sales by Regions
5.8 Melanoma (lesions) Historic and Forecast Sales by Regions
5.9 Beta-Thalassemia Major/SCD Historic and Forecast Sales by Regions
5.10. Head & Neck Squamous Cell Carcinoma Historic and Forecast Sales by Regions
5.11 Peripheral arterial disease Historic and Forecast Sales by Regions
5.12 Spina...
